The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function.
- Author:
Yong ZHANG
1
;
De-lin GUAN
;
Cheng-qing XIA
;
Zhi-you HAN
;
Jian-jun XU
;
Ju-zhong GAO
;
Ke-rang WU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Antigens, CD; blood; Dual Specificity Phosphatase 2; Female; Graft Rejection; Humans; Integrin beta3; blood; Kidney; physiopathology; Kidney Transplantation; Male; Middle Aged; Platelet Activation; Platelet Membrane Glycoproteins; Protein Phosphatase 2; Protein Tyrosine Phosphatases; blood; Tetraspanin 30
- From: Chinese Journal of Surgery 2003;41(12):881-884
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo explore the relationships between the peripheral blood levels of CD61, CD63, PAC-1 and the incidence of acute rejection and tubular necrosis after renal transplantation, and recovery of the graft function.
METHODSThe peripheral blood levels of CD61, CD63, and PAC-1 of 86 patients with uremia in different stages before and after transplantations were analyzed by flow cytometry. The patients were divided into three groups: (1) twenty-nine patients with normal grafts function, (2) hirty with acute rejection and (3) twenty-seven with acute tubular necrosis. The patients with acute rejection were randomly divided into treatment group with anticoagulants and cntrol group.
RESULTSThe peripheral blood levels of CD61, CD63 and PAC-1 significantly increased (P < 0.05) in the patients with acute rejection, in comparison with those with normal grafts function and those with acute tubular necrosis. The peripheral blood levels of CD61, CD63 and PAC-1 in patients with acute rejection in anticoagulants therapy was lower, recovery time of the grafts function was shorter, one-year survival rates of patients and grafts were higher, as compared with those of controls.
CONCLUSIONSThe patients with acute rejection have significantly high peripheral blood levels of CD61, CD63 and PAC-1 before transplantation, however, these values in patients with acute tubular necrosis are not high, this suggesting that acute rejection might relate to platelet activation, while acute tubular necrosis might not relate to it. After anticoagulants therapy in patients with acute rejection, the grafts function might recover faster and their one-year survival rates and grafts might be higher in those with CD61, CD63 and PAC-1 decreasing remarkably.